APR-246

Eprenetapopt plus venetoclax and azacitidine in the treatment of TP53-mutated AML 1:36
Eprenetapopt plus venetoclax and azacitidine in the treatment of TP53-mutated AML
David Sallman • 11 Dec 2021
Updates in the treatment landscape of p53-mutated AML/MDS 1:26
Updates in the treatment landscape of p53-mutated AML/MDS
Rory Shallis • 12 Dec 2021
Current and emerging treatment options for MDS 4:28
Current and emerging treatment options for MDS
Jacqueline Garcia • 14 Jan 2022
Key MDS updates from the 2021 ASH meeting 2:00
Key MDS updates from the 2021 ASH meeting
Amer Zeidan • 12 Dec 2021
Long-term follow-up: Phase II study of APR-246 + aza in TP53-mutated MDS & AML 2:58
Long-term follow-up: Phase II study of APR-246 + aza in TP53-mutated MDS & AML
Thomas Cluzeau • 20 Sep 2021
Progress in the treatment of TP53 mutated AML 8:14
Progress in the treatment of TP53 mutated AML
Naval Daver • 26 Aug 2021
TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax 1:48
TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax
Kunhwa Kim • 17 Dec 2020
Using an animated patient’s guide to improve understanding of MDS 1:17
Using an animated patient’s guide to improve understanding of MDS
David Sallman • 10 Dec 2020
Promising therapies on the horizon for MDS 4:26
Promising therapies on the horizon for MDS
Maria Teresa Voso • 29 Jan 2021
Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246 5:05
Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246
Valeria Santini • 25 Jan 2021
Novel therapies in the future of MDS treatment 2:43
Novel therapies in the future of MDS treatment
Felicitas Thol • 22 Jan 2021
APR-246 combination treatments in TP53-mutant R/R NHLs 2:48
APR-246 combination treatments in TP53-mutant R/R NHLs
Meghan Thompson • 8 Dec 2020
The 2020 highlights in MDS 4:47
The 2020 highlights in MDS
Thomas Cluzeau • 30 Sep 2020
MDS: state of the art in Europe 4:10
MDS: state of the art in Europe
Valeria Santini • 10 Sep 2020
Advances and challenges in AML treatment 8:08
Advances and challenges in AML treatment
Naval Daver • 3 Sep 2020
APR-246 in TP53 mutated MDS and AML 3:00
APR-246 in TP53 mutated MDS and AML
David Sallman • 3 Sep 2020
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals